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Abstract 
Acanthosis nigricans (AN) is a hyperpigmented keratotic skin lesion known to be associated 
with malignant disease and endocrinopathy. We report a very rare case of generalized AN 
with Sjögren’s syndrome- and systemic lupus erythematosus-like features but without type B 
insulin resistance. Neither internal malignancy nor other endocrinological disorders, 
including glucose intolerance, were detected during a 10-year clinical course with benign 
diffuse papillomatosis extending from the mucosa of the larynx to the esophagogastric 
junction. The case was complicated with chronic thyroiditis and interstitial pneumonia, 
which were not treated with any medication. AN skin lesions and mucosal papillomatosis 
regressed with oral cyclosporine A, accompanied by the lowering of autoantibody titers. This 
is the first report of generalized AN involving an area from the mucosa of the larynx to the 
esophagogastric junction accompanied by autoimmune manifestations which responded to 
systemic immunosuppressive therapy. 
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Introduction 
Acanthosis nigricans (AN) is a disorder characterized by skin hyperpigmentation 
and thickening, especially in certain regions such as the neck, axillae, and mucosa. AN is 
well known as a clinical marker of malignancy; however, most cases are related to 
metabolic or endocrinological diseases such as insulin-resistant diabetes mellitus, 
hypothyroidism, and obesity [1–5]. In some cases, autoimmune disorders such as 
systemic lupus erythematosus (SLE) and hypothyroidism complicated with type B 
insulin resistance were reported to be accompanied by AN [6–12]. 
Here, we report a first case of generalized AN involving an area from the mucosa of 
the larynx to the esophagogastric junction, accompanied by autoimmune 
manifestations but not type B insulin resistance. Our case responded well to systemic 
immunosuppressive therapy using cyclosporine A (CsA). 
Case Report 
A 58-year-old Japanese male had noticed a diffuse pigmentation of his face and generalized 
hypotrichosis 10 years before his first visit to our clinic. He had been diagnosed with AN at the age of 
55 years because of mucocutaneous manifestations such as diffuse papillomatosis. No internal 
malignancy was detected during repeated medical examinations over a 10-year clinical course. He 
was referred to our outpatient clinic in June 2006. His height was 168.5 cm and his weight 59 kg 
(body mass index 20.7). He presented with dirty-looking keratosis of the umbilicus, areola, and chest 
wall, diffuse papillomatosis of the palms and soles in addition to numerous acrochordons of the face, 
neck, and axilla. Hyperplastic and papillomatous changes of the lips and oral cavity accompanied by 
impaired taste sensation were also noted (fig. 1a–d). His past medical history showed interstitial 
pneumonia and chronic thyroiditis. He did not have any familial history of endocrine disorders, 
including AN. The biopsy specimens taken from skin of the posterior neck and mucosa of the pharynx 
and larynx revealed slight hyperkeratosis and acanthosis undulating with dermal papillomatosis (fig. 
2a, c). Upper endoscopy showed a diffuse papillomatosis extending from the mucosa of the larynx to 
the esophagogastric junction, where little normal mucosa was left (fig. 2b). No epidermal inclusion 
bodies were observed and polymerase chain reaction analysis of human papilloma virus DNA in the 
mucosal region was negative. These findings were compatible with a diagnosis of AN [1, 13–15]. 
Biochemical and serological examinations yielded the following results: serum immunoglobulin 
IgG 2,270 mg/dl, antinuclear antibody (ANA) titer 1/1,280 (homogenous pattern), anti-ss/ds DNA 
antibodies 580/60.8 IU/ml, LE test positive, antimicrosomal antibody titer 1/25,600, and 
anticardiolipin antibodies 13.0 U/ml. Although anti-SS-A/SS-B antibody and gum and Schirmer’s tests 
showed negative results, lip biopsy and Tc-99m scintigraphy of the salivary gland revealed chronic 
sialadenitis. Thyroid-stimulating hormone, free thyrotropin3 (F-T3) and F-T4 showed normal levels, 
and both insulin antibody and insulin receptor antibody were negative. Based on the result of the 75-
gram oral glucose tolerance test and HbA1c (6.1%), the patient was classified as borderline diabetes 
mellitus. HOMA-R, a useful surrogate index of insulin resistance which is calculated by using fasting 
serum insulin, was in the normal range (normal range <2.5, our case 0.96). For the detection of 
internal malignancy, we repeatedly performed instrumental and serological examinations. Tumor 
markers showed a normal range, and a CT scan showed only an interstitial pattern in the bilateral 
lung. PET scans revealed an uptake of radioisotope from the pharynx to the stomach, but upper 
endoscopy did not show any carcinomatous changes. Taken together, these findings resulted in a 
diagnosis of autoimmune AN without type B insulin resistance. Our patient’s former treatments 
included etretinate and vitamin D ointment, with poor clinical response. As we suspected that his AN 
skin lesions were associated with autoimmune conditions, and as we could confirm that his lesions 
were not complicated by internal malignancy, administration of oral CsA 150 mg (2.5 mg/kg) was 
initiated, which gradually resolved the papillomatosis of the lip, keratosis of the umbilicus, 
papillomatous polyp of the larynx, and generalized hypotrichosis (fig. 3a–d). ANA titers decreased 
from 1/1,280 to 1/160 and anti-DNA antibody from 60.4 to 24 IU/ml. CsA was discontinued after 8  
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months because new small nodules in the lung, which could have been malignant, were detected by 
CT. Later, these lesions were pathologically diagnosed as inflammatory changes. After discontinuation 
of CsA therapy, the AN skin lesions gradually worsened, followed by the appearance of small nodules 
in the mesentery, which were pathologically diagnosed as benign. 
Discussion 
The term AN was originally proposed by Unna, although the first case was described 
by Pollitzer and Janovsky as early as 1891 [1–3]. Curth classified AN into malignant, 
benign, and syndromic or pseudo AN [16]. Malignancy-associated AN tends to be 
extensive and involves mucosal surfaces, mostly in elderly people. The majority of 
associated malignancies are intra-abdominal adenocarcinomas, most commonly gastric 
cancer [1, 13, 15]. In our case, the results of repeated examinations over a 10-year 
clinical course excluded malignancy-associated AN. However, careful examinations for 
malignancy are needed as the patient may develop malignancy in the future. In 1981, 
Sturner et al. [12] reported that some patients with AN who are positive for ANA or 
show increased immunoglobulin levels might be associated with disordered 
immunoreactivity not fitting any clinically recognizable syndromes. In our case, SLE 
and Sjögren’s syndrome were strongly suspected from the clinical data; however, he 
did not meet the criteria of these diseases. CsA was chosen as a treatment of skin and 
mucosal manifestation in our case. There are no previous reports that describe CsA as a 
treatment of generalized AN. Based on the speculation that some autoimmune 
manifestations might have induced the hyperkeratotic and proliferative symptoms, 
administration of CsA was started. CsA gradually reduced both the papillomatous skin 
and mucosal lesions of AN in conjunction with a decrease in ANA titers, but reversal 
occurred, accompanied by a worsening of symptoms, after discontinuation of CsA 
treatment. 
The precise etiology of AN has remained unclear. In general, SLE and related 
conditions accompanied by AN are, at most, positive for anti-insulin receptor 
antibodies and often present with severe hyperglycemia and insulin resistance (type B 
insulin resistance), which might be a cause of AN-associated skin lesions. Insulin-like 
growth factor 1 receptor (IGFR) is expressed on the surface of human keratinocytes 
and fibroblasts, while excessive amounts of serum insulin interact with IGFR in 
peripheral tissues. Binding of insulin to IGFR promotes proliferation of fibroblasts and 
keratinocytes, which subsequently lead to AN [1]. However, the generalized AN in our 
case, with Sjögren’s syndrome- and SLE-like features, was not associated with type B 
insulin resistance, and was effectively treated with CsA. We speculate that some 
unknown autoantibodies other than the insulin-receptor antibody might have similar 
effects on the generation of AN mucocutaneous lesions. This may be one reason why 
CsA was effective in treating the AN lesions. In situations where complications of both 
internal malignancies and diabetes mellitus can be excluded after very careful and 
intensive examinations, CsA can be expected to be an effective therapy for AN with 
autoimmune manifestations. Further investigation is needed to determine the 
pathological aspects that make CsA therapy effective for AN.  
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Fig. 1. Clinical appearance of the patient at the initial visit in 2006. a Diffuse pigmentation of his face 
and generalized hypotrichosis. b Hyperplastic and papillomatous changes of the oral cavity. c, d Dirty 
keratosis of the palms and soles. 
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Fig. 2. Histological findings. a, c Histological features of biopsy specimen from posterior neck (a, 
magnification ×40) and larynx (c, magnification ×200). Slight hyperkeratosis and acanthosis were 
seen undulating with dermal papillomatosis. b Upper endoscopy feature. A diffuse papillomatosis 
extending to the esophagus, where little normal mucosa was left. Carcinomatous changes such as 
ulcers or nodules were not observed.  
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Fig. 3. Papillomatosis of the lip (a, b) and polyp of the larynx (c, d; arrow) before (a, c) and after (b, d) 
CsA therapy. 
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